The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2022 | Highlights in the field of lymphoma from ASCO 2022
Andre Goy, MD, John Theurer Cancer Center, Hackensack, NJ, shares his highlights from the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting, including the Phase III SHINE trial (NCT01776840) demonstrating for the first time that the addition of ibrutinib to bendamustine-rituximab provides a clinical benefit to patients with mantle cell lymphoma (MCL). Additionally, data on next-generation sequencing (NGS) based on liquid biopsies exploring DNA and RNA signatures illustrated the utility of NGS for stratifying patients with large B-cell lymphoma (LBCL) beyond the standard germinal center (GC) and non-GC classifications. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
